Wells Fargo Maintains Outperform On Gilead Sciences Following Harvoni/Sovaldi...
In a research report issued this morning, analyst Brian Abrahams of Wells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ:GILD), as GILD’s Harvoni/Sovaldi IMS data weekended 11/28/14...
View ArticleJefferies Dive In on Two Healthcare Stocks: Gilead Sciences, Inc. (GILD) and...
Analyst Brian Abrahams from Jefferies provides his insight on the different drug developments concerning Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG). Below, the analyst...
View ArticleJefferies Remains Sidelined on Gilead Sciences, Inc. (GILD) Following...
Jefferies analyst Brian Abrahams is out with a research report on shares of Gilead Sciences, Inc. (NASDAQ:GILD), reiterating a Hold rating on GILD, while trimming the price target from $93 to $91, on...
View ArticleJefferies Reiterates Upbeat View on Biogen Inc (BIIB) Following Fast Track...
Biogen Inc (NASDAQ:BIIB) indicated in its brief PR update yesterday that its pipeline drug aducanumab, the firm’s investigational treatment for early Alzheimer’s disease (AD), received Fast Track...
View ArticleJefferies Positive on Gilead Sciences, Inc. (GILD) Following Dinner with...
Jefferies analyst Brian Abrahams provides insight on shares of Gilead Sciences, Inc. (NASDAQ:GILD) on the heels of hosting a dinner with a leading infectious disease specialist involved in patient care...
View ArticleJefferies Reiterates Upbeat View on Marinus Pharmaceuticals Inc (MRNS) Amid...
Yesterday, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced more complete data from the exploratory Phase II study in 11 children with uncontrolled seizures due to the PCDH19 mutation, which showed...
View ArticleJefferies Weighs in on Celgene Corporation (CELG) Following Presentation of...
In Vienna, Austria at the United European Gastroenterology Week (UEGW) Conference held from October 15th through the 19th, Celgene Corporation (NASDAQ:CELG) announced new data from its randomized,...
View ArticleWhat to Expect from Gilead Sciences, Inc. (GILD) Amid M&A Buzz and Upcoming...
Analysts see an interesting path ahead for Gilead Sciences, Inc. (NASDAQ:GILD), between exciting collaborative possibilities and its pipeline catalysts that have brought bullish notes across the board...
View Article
More Pages to Explore .....